GI Oncology
Conference Coverage
Add-on nab-paclitaxel extends survival in metastatic pancreatic cancer
Major Finding: Median overall survival in patients with metastatic pancreatic cancer increased from 6.7 months on gemcitabine to 8.5 months on nab...
News
Bevacizumab boosts capecitabine response in elderly with metastatic colorectal cancer
Major Finding: Progression-free survival improved from 5.1 months on capecitabine to 9.1 months on capecitabine plus bevacizumab in elderly...
News
Adding cetuximab to chemoradiotherapy harmful in esophageal cancer
Major Finding: Adding cetuximab to chemoradiotherapy for localized esophageal cancer was associated with significantly shorter median survival...
News
Prostatectomy vs. radiotherapy: 15-year functional outcomes are same
Major Finding: At 15-year follow-up, there were no significant differences in urinary, bowel, or sexual function between 1,164 men who had...
News
FDA approves bevacizumab for second-line combinations
News
Resecting residual gastrointestinal stromal tumors improved survival
Major Finding: Time to tumor progression was 88 months in 42 patients who had surgery for residual disease and 42 months in 92 patients given...
News
Second-line docetaxel benefits seen for esophagogastric cancers
Major Finding: Docetaxel significantly increased overall survival from a median of 3.6 months to 5.2 months and reduced pain scores in patients...
News
Statins cut risk of hepatocellular carcinoma
Major Finding: Statin therapy reduced the risk of developing hepatocellular carcinoma by 37% overall; the risk reduction was stronger (48%) in...
News
Ten percent of neoplastic polyps may be incompletely resected
Major Finding: Ten percent of neoplastic polyps (5-20 mm) were not resected completely, as evidenced by neoplastic tissue in biopsies from the...
News
Poor performance seen after optical biopsy training
Major Finding: Three of 12 community gastroenterologists learned to distinguish adenomatous from hyperplastic colon polyps 5 mm in size or smaller...
News
Tivantinib Shows Modest Benefit in Relapsed Liver Cancer
Major Finding: Median time to progression, the primary end point, was 6.9 weeks for patients randomized to tivantinib, compared with 6.0 weeks for...